ReviewFrontiers in oncology2018
Metastatic Extramammary Paget's Disease: Pathogenesis and Novel Therapeutic Approach.
Review in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 79 citations in OpenAlex.
- Carelizumab and rivoceranib for advanced extramammary Paget's disease: an investigator-initiated multicenter, single-arm, phase II trial.The oncologist · 2025Trial
- Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.JCO precision oncology · 2022Trial
- Boron neutron capture therapy for vulvar melanoma and genital extramammary Paget's disease with curative responses.Cancer communications (London, England) · 2018Trial
- Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report.Gynecologic oncology reports · 2026Article
- Concurrent chemoradiotherapy for metastatic vulvar extramammary Paget's disease involving supraclavicular nodes: a case report.Radiation oncology journal · 2026Article
- Article
- Trastuzumab monotherapy as maintenance treatment for metastatic HER2+ vulvar Paget disease: systematic review and case report.Gynecologic oncology reports · 2025Review
- Targeting tumor-associated macrophages: Novel insights into immunotherapy of skin cancer.Journal of advanced research · 2025Review
- Establishment of a trastuzumab-resistant extramammary Paget disease model: loss of PTEN as a potential mechanism.British journal of cancer · 2024Article
- The Role of Line-Field Confocal Optical Coherence Tomography in Detecting Extramammary Paget Disease Recurrences: A Pilot Diagnostic Study.Diagnostics (Basel, Switzerland) · 2024Article
- A rare case of extramammary Paget disease in a young HIV-positive man.JAAD case reports · 2024Article
- Case report: Disitamab vedotin combined with immunotherapy demonstrated excellent efficacy in scrotal Paget's disease with Her-2 overexpression.Frontiers in immunology · 2024Article
- Tislelizumab plus chemotherapy in metastatic extramammary Paget disease after surgery: a case report.Frontiers in oncology · 2024Article
- Independent Risk Factors for Postoperative Recurrence of Patients with Primary Extramammary Paget's Disease: A Retrospective Analysis.Clinical, cosmetic and investigational dermatology · 2024Article
- Article
- Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG-RC20-06.Cancer medicine · 2023Article
- Perianal extramammary Paget's disease with adenocarcinoma of perianal skin area, a case report.Journal of surgical case reports · 2023Article
- Review
- Docetaxel treatment for widely metastatic invasive vulvar extramammary Paget's disease with multifocal bone metastasis.Gynecologic oncology reports · 2023Article
- Extramammary Paget's disease: Updates in the workup and management.Asian journal of urology · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extramammary Paget's disease (EMPD) is a rare, slow-growing, cutaneous adenocarcinoma that usually originates in the anogenital area and axillae outside the mammary glands. EMPD mostly progresses slowly and is often diagnosed as carcinoma
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.